Compare Natera Inc. Common Stock (NTRA) vs Schwab US Dividend Equity ETF (SCHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Schwab US Dividend Equity ETF — how do they compare? Natera Inc. Common Stock trades at $394.6 (market cap $57.03B), while Schwab US Dividend Equity ETF trades at $33.91 (market cap $111.61B). The key difference: Schwab US Dividend Equity ETF is the larger of the two by market cap, and Schwab US Dividend Equity ETF is more actively traded (22,238,193 versus 1,131,157). Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Schwab US Dividend Equity ETF for 64 Days on average.
| NTRA | SCHD | |
|---|---|---|
Market Cap | $57.03B | $111.61B |
Volume | 1,131,157 | 22,238,193 |
Sector | Health | Broad Market / Factor |
52-Week High | $425.64 | $35.21 |
52-Week Low | $179.42 | $26.44 |
Typical Hold Time | 0 Days | 64 Days |
Enterprise Value | $56.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
SCHD trades at $33.37, up 0.33% with a bullish technical signal from moving averages. Recent news highlights SCHD outperforming the S&P 500 in 2026 and growing its dividend. The ETF's defensive dividend strategy faces scrutiny after missing gains from stocks like Broadcom due to its selection rules.
The outlook remains positive for income investors seeking quality dividend growth with lower risk through diversification. Key risks include interest rate sensitivity and the opportunity cost of excluded high-growth stocks. Current technical strength supports near-term stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →
